Cargando…
Optimized PD-L1 scoring of gastric cancer
BACKGROUND: PD-1/PD-L1-Immunotherapy has been approved for gastric carcinoma. PD-L1 assessment by immunohistochemistry is the principle biomarker. Are biopsies able to map the actual PD-L1 status of the entire tumor? METHODS: Whole tumor slides of 56 gastric carcinoma were analyzed to determine the...
Autores principales: | Schoemig-Markiefka, Birgid, Eschbach, Jana, Scheel, Andreas H., Pamuk, Aylin, Rueschoff, Josef, Zander, Thomas, Buettner, Reinhard, Schroeder, Wolfgang, Bruns, Christiane J., Loeser, Heike, Alakus, Hakan, Quaas, Alexander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8338825/ https://www.ncbi.nlm.nih.gov/pubmed/33954872 http://dx.doi.org/10.1007/s10120-021-01195-4 |
Ejemplares similares
-
Amplification of KRAS and its heterogeneity in non-Asian gastric adenocarcinomas
por: Rehkaemper, Jan, et al.
Publicado: (2020) -
Occurrence of High Microsatellite-Instability/Mismatch Repair Deficiency in Nearly 2,000 Human Adenocarcinomas of the Gastrointestinal Tract, Pancreas, and Bile Ducts: A Study From a Large German Comprehensive Cancer Center
por: Quaas, Alexander, et al.
Publicado: (2021) -
Sex-specific prognostic effect of CD66b-positive tumor-infiltrating neutrophils (TANs) in gastric and esophageal adenocarcinoma
por: Quaas, Alexander, et al.
Publicado: (2021) -
Tumour area infiltration and cell count in endoscopic biopsies of therapy-naive upper GI tract carcinomas by QuPath analysis: implications for predictive biomarker testing
por: Scheel, Andreas H., et al.
Publicado: (2023) -
Mesothelin expression in esophageal adenocarcinoma and squamous cell carcinoma and its possible impact on future treatment strategies
por: Moentenich, Valeska, et al.
Publicado: (2020)